These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 10811079)

  • 1. Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy.
    Nousiainen I; Kälviäinen R; Mäntyjärvi M
    Ophthalmology; 2000 May; 107(5):884-8. PubMed ID: 10811079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Color vision and macular recovery time in epileptic adolescents treated with valproate and carbamazepine.
    Verrotti A; Lobefalo L; Tocco AM; Spalice A; Gallenga PE; Chiarelli F; Iannetti P
    Eur J Neurol; 2006 Jul; 13(7):736-41. PubMed ID: 16834703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Color vision and contrast sensitivity in epilepsy patients treated with initial tiagabine monotherapy.
    Sorri I; Kälviäinen R; Mäntyjärvi M
    Epilepsy Res; 2005 Dec; 67(3):101-7. PubMed ID: 16257182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Color vision in epileptic adolescents treated with valproate and carbamazepine.
    Verrotti A; Lobefalo L; Priolo T; Rapinese M; Trotta D; Morgese G; Gallenga PE; Chiarelli F
    Seizure; 2004 Sep; 13(6):411-7. PubMed ID: 15276145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual function in epilepsy patients treated with initial valproate monotherapy.
    Sorri I; Rissanen E; Mäntyjärvi M; Kälviäinen R
    Seizure; 2005 Sep; 14(6):367-70. PubMed ID: 15939631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients treated with vigabatrin exhibit central visual function loss.
    Hilton EJ; Cubbidge RP; Hosking SL; Betts T; Comaish IF
    Epilepsia; 2002 Nov; 43(11):1351-9. PubMed ID: 12423385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Disorders of color perception and increase glare sensitivity in phenytoin and carbamazepine therapy. Ocular side effects of anticonvulsants].
    Bayer A; Thiel HJ; Zrenner E; Paulus W; Ried S; Schmidt D
    Nervenarzt; 1995 Feb; 66(2):89-96. PubMed ID: 7715759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects.
    Kälviäinen R; Nousiainen I; Mäntyjärvi M; Nikoskelainen E; Partanen J; Partanen K; Riekkinen P
    Neurology; 1999 Sep; 53(5):922-6. PubMed ID: 10496247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Color vision tests for early detection of antiepileptic drug toxicity.
    Bayer AU; Thiel HJ; Zrenner E; Dichgans J; Kuehn M; Paulus W; Ried S; Schmidt D
    Neurology; 1997 May; 48(5):1394-7. PubMed ID: 9153479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Color vision in Stargardt's disease.
    Mäntyjärvi M; Tuppurainen K
    Int Ophthalmol; 1992 Nov; 16(6):423-8. PubMed ID: 1490833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of antiepileptic drugs on visual function, with special reference to Vigabatrin.
    Sorri I
    Acta Ophthalmol Scand; 2002 Jun; 80(3):343-4. PubMed ID: 12059879
    [No Abstract]   [Full Text] [Related]  

  • 12. Vigabatrin versus carbamazepine monotherapy for epilepsy.
    Xiao Y; Gan L; Wang J; Luo M; Luo H
    Cochrane Database Syst Rev; 2012 Jan; 1():CD008781. PubMed ID: 22258989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vigabatrin versus carbamazepine monotherapy for epilepsy.
    Xiao Y; Gan L; Wang J; Luo M; Luo H
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008781. PubMed ID: 26580100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of color perception in individuals addicted to narcotic substances in the Farnsworth-Munsell 100-Hue test].
    Nadolska K; Goś R
    Med Pr; 2016 Dec; 67(6):777-785. PubMed ID: 28005086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of colour vision in epileptic patients exposed to single-drug therapy.
    López L; Thomson A; Rabinowicz AL
    Eur Neurol; 1999; 41(4):201-5. PubMed ID: 10343150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual field constriction and electrophysiological changes associated with vigabatrin.
    Besch D; Kurtenbach A; Apfelstedt-Sylla E; Sadowski B; Dennig D; Asenbauer C; Zrenner E; Schiefer U
    Doc Ophthalmol; 2002 Mar; 104(2):151-70. PubMed ID: 11999623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A controlled study of vigabatrin and visual abnormalities.
    Manuchehri K; Goodman S; Siviter L; Nightingale S
    Br J Ophthalmol; 2000 May; 84(5):499-505. PubMed ID: 10781514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual defects associated with vigabatrin: a study of epileptic argentine patients.
    Moreno MC; Giagante B; Saidon P; Kochen S; Benozzi J; Rosenstein RE
    Can J Neurol Sci; 2005 Nov; 32(4):459-64. PubMed ID: 16408575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making.
    Paul SR; Krauss GL; Miller NR; Medura MT; Miller TA; Johnson MA
    Epilepsia; 2001 Apr; 42(4):525-30. PubMed ID: 11440348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers.
    Nousiainen I; Kälviäinen R; Mäntyjärvi M
    Br J Ophthalmol; 2000 Jun; 84(6):622-5. PubMed ID: 10837389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.